Dodging a dogma: is treating beyond progression beneficial? Cancer Chemother Pharmacol 2013 May;71(5):1385-6
Date
02/28/2013Pubmed ID
23443308DOI
10.1007/s00280-013-2123-zScopus ID
2-s2.0-84877926446 (requires institutional sign-in at Scopus site) 6 CitationsAuthor List
Naing A, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsDisease Progression
Drug Resistance, Neoplasm
Humans
Neoplasms
Treatment Outcome
